Effect of
AD-1590 on allergic
inflammations was investigated.
AD-1590 and
indomethacin at an oral dosage as high as 32 mg/kg did not show any significant inhibitory activity on rat passive cutaneous anaphylaxis, a type-I
allergy, although
prednisolone and
cyproheptadine produced strong inhibition. Against rat
adjuvant arthritis, type-III and -IV
allergies,
AD-1590 showed potent prophylactic (2 and 4 mg/kg/day) and therapeutic (0.4-1 mg/kg/day) effects when given orally once a day for 3 weeks beginning from just before and for 1 week starting from 14 to 18 days after adjuvant inoculation, respectively; however, its prophylactic and therapeutic potencies were about one-fourth and one-fifth, respectively, that of
indomethacin. The
arthritis was strongly inhibited with prophylactic treatment of
prednisolone (1 mg/kg/day) or
cyproheptadine (40 mg/kg/day). On the other hand,
prednisolone (ED50 = 0.0119 mg/ear, topical) showed strong activity in inhibiting mouse
contact hypersensitivity to
oxazolone (ear
edema), a type-IV
allergy, but
cyproheptadine only had weak activity.
AD-1590 (0.318 mg/ear) and
indomethacin (0.699 mg/ear) produced rather strong inhibition; in particular,
AD-1590 produced almost complete inhibition at high dosages, whereas most of the non-steroidal anti-inflammatory drugs (
NSAID) tested showed weak inhibition or a partial inhibition of about 50% even at the highest dosage. The oral potency of
AD-1590 was about 2 and 100 times those of
indomethacin and
ibuprofen, respectively. These results demonstrate that in allergic
inflammation, the pharmacological properties of
AD-1590 are somewhat different from those of other
NSAID and different from those of
prednisolone and
cyproheptadine.